Kevin Chartier

Kevin Chartier, as Principal Advisor of Biostatistics and Submissions Planning, Kevin works with the biostatistics team across MMS global operations to support Sponsors with complex studies, programs and submissions across various therapeutic areas and extending to rare diseases. In addition, he acts as the senior technical reviewer for complex biostatistics studies and advises Sponsors on both overall and quantitative specific methods and efficiencies at the protocol and project level, leading to health authority submissions.

Prior to MMS, Kevin has held positions at Astellas Pharma, Novartis, United BioSource Corporation, Wyeth, Pfizer, and Harris Laboratories. He completed his Ph.D. in Statistics from Kansas State University.

Suggested For You

perspectives

June 13th, 2025

Applying Artificial Intelligence (AI) and Real-World Evidence to Boost Efficiency in Patient Safety Narratives 

perspectives

June 11th, 2025

Choosing the Right Strategy: Parallel, Sequential, and Staggered Regulatory Submissions 

news

May 28th, 2025

MMS Named Finalist for Fierce CRO Award in Excellence in Client Service and Partnership, CEO shortlisted for the CRO Champion Award